Triple AAV delivery restores a protein long considered out of reach
A new preclinical strategy has reopened a long-standing problem in Duchenne muscular dystrophy: how to replace a gene so large that it cannot fit inside a standard adeno-associated viral vector. Dystrophin is encoded by an 11.2 kb segment of DMD mRNA, far beyond the roughly 4.7 kb packaging ceiling of AAV. Rather than shrinking the protein into a truncated surrogate, investigators used three separate AAVs and split inteins to rebuild the full-length molecule inside muscle cells.
The approach matters because dystrophin is not a peripheral structural accessory. It is a core stabilizer of the muscle membrane, and loss of the full protein leaves skeletal and cardiac muscle vulnerable to repeated injury. A method that can reconstitute the intact protein offers a more biologically faithful replacement strategy than partial constructs can provide.
Here, triple AAV codelivery enabled expression of full-length dystrophin from three fragments. The design depended on protein trans-splicing mediated by split inteins, a biochemical trick that lets separately delivered pieces assemble into a single final product after delivery. In practical terms, the strategy sidesteps the cargo problem without abandoning the therapeutic goal of restoring the native protein.
Split inteins enabled reconstitution of the native protein from three fragments
The study identified an efficient and specific split intein pair that supported reassembly of dystrophin from three fragments. Specificity is not a minor technical detail in this setting. If the fragments fail to meet precisely, or if the reassembly step is inefficient, the entire platform collapses before a therapeutic protein ever reaches the sarcolemma.
Systemic delivery of low doses of the myotropic AAVMYO1 vector produced efficient full-length dystrophin expression in the hind limb, diaphragm, and heart of mdx4cv mice. Those tissues matter for obvious clinical reasons: limb muscle determines mobility, the diaphragm governs ventilatory reserve, and the heart carries the burden of the cardiomyopathy that drives much of the morbidity in Duchenne muscular dystrophy. A delivery system that reaches all three compartments with low vector doses directly addresses one of the central hurdles in gene replacement therapy.
The low-dose aspect is clinically relevant even in a mouse study. AAV-based programs often run into tradeoffs between efficacy and vector burden, especially when systemic distribution is needed across large muscle groups. Lower doses reduce the amount of material required to achieve expression and may help preserve feasibility for larger bodies, larger target tissues, and diseases where repeat systemic exposure is difficult.
A stark result emerged from the treated mice: muscle morphology and physiology improved significantly compared with saline-treated controls. The difference was not confined to a molecular readout on a blot or an isolated histologic feature. It extended to the structural and functional consequences expected when dystrophin returns to muscle fibers that have spent their lives mechanically exposed and under-protected.
Muscle architecture and physiology improved across limb, diaphragm, and heart
The study’s central biological implication is straightforward. If a cell can be persuaded to rebuild the full-length dystrophin scaffold, then membrane stability, force transmission, and tissue resilience should improve together. That is the logic behind the observed reversal of muscular dystrophy defects in both young and old mice. The treated animals were not merely expressing a transgene; they were showing a phenotype that moved in the direction of restored muscle health.
Age did not block the approach in this model. Full-length dystrophin expression reversed defects in young and old mdx4cv mice, suggesting that the platform retained activity in a setting where muscle disease had already progressed beyond early injury alone. For a disorder like Duchenne muscular dystrophy, where patients are rarely treated at the very first molecular insult, the ability to act in older tissue is a meaningful preclinical signal.
The heart deserves separate attention. Cardiac involvement is a major determinant of outcome in Duchenne muscular dystrophy, and a therapy that reaches cardiac muscle with functional protein expression moves closer to the disease biology that actually drives clinical decline. The diaphragm carries similar weight because respiratory muscle weakness is among the most consequential downstream effects of dystrophin deficiency. A platform that reaches both organs alongside limb muscle is therefore more than a proof of expression; it is a proof of distribution in tissues that matter.
The work also extends beyond Duchenne muscular dystrophy itself. Full-length dystrophin is only one example of the broader class of large genes that sit outside standard AAV cargo limits. The same split-intein, multi-vector concept could be adapted to other disorders in which gene replacement has stalled because the therapeutic gene is too large for a single viral payload. In that sense, the study offers a delivery architecture rather than a disease-specific fix.
Even so, the translational path remains defined by the constraints visible in the experiment. This is a preclinical mouse study, and the abstract does not provide evidence of long-term durability, immune tolerance, or human safety. It does show something more foundational: large proteins can be rebuilt from multiple delivered fragments using myotropic AAV vectors, and the reconstructed product can improve muscle structure and function in a Duchenne model. For a field long limited by vector size, that is an important technical advance with direct relevance to future gene replacement strategies.